

Efficacy and Safety of Durvalumab in Locally Advanced Carcinoma

JAMA Oncology

3, e172411

DOI: [10.1001/jamaoncol.2017.2411](https://doi.org/10.1001/jamaoncol.2017.2411)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Trial watch: Immune checkpoint blockers for cancer therapy. <i>OncolImmunology</i> , 2017, 6, e1373237.	2.1	62
2	Immunotherapy in the Elderly. <i>European Urology Focus</i> , 2017, 3, 403-412.	1.6	16
3	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225
4	A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	0.9	34
5	Biomarkers for immunotherapy in bladder cancer: a moving target. , 2017, 5, 94.		144
6	Current markers and their value in the era of immuno-oncology. <i>Translational Andrology and Urology</i> , 2017, 6, 1111-1116.	0.6	6
7	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 16.	1.3	5
8	Durvalumab in urothelial cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 311-318.	1.1	8
9	Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?. <i>European Urology</i> , 2018, 74, 63-65.	0.9	4
10	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	1.7	14
11	Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. <i>BioDrugs</i> , 2018, 32, 221-231.	2.2	22
12	Clinical Trials Corner. <i>Bladder Cancer</i> , 2018, 4, 133-136.	0.2	0
13	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
14	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. <i>Urologic Clinics of North America</i> , 2018, 45, 287-295.	0.8	10
15	Recent developments in the treatment of advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 109-114.	0.8	34
16	Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 103-108.	0.8	20
17	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
19	Role of immunotherapy in bladder cancer: past, present and future. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 629-645.	1.1	35

#	ARTICLE	IF	CITATIONS
20	Nivolumab for the treatment of urothelial cancers. Expert Review of Anticancer Therapy, 2018, 18, 215-221.	1.1	18
21	Pembrolizumab for the treatment of bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 107-114.	1.1	12
22	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist, 2018, 23, 410-421.	1.9	23
23	Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma. Clinical Pharmacology and Therapeutics, 2018, 103, 643-652.	2.3	35
24	Antibodies to watch in 2018. MAbs, 2018, 10, 183-203.	2.6	223
25	Genitourinary Malignancies. , 2018, , 79-94.		0
26	PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Diagnostic Pathology, 2018, 13, 5.	0.9	23
27	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, e961-e967.	0.9	14
28	<scp>CD8</scp> lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Reports, 2018, 1, e1002.	0.6	8
31	Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452.	6.6	1,437
32	Recent advances in medical therapy for metastatic urothelial cancer. International Journal of Clinical Oncology, 2018, 23, 599-607.	1.0	30
33	The emerging role of immunotherapy in advanced urothelial cancers. Current Opinion in Oncology, 2018, 30, 172-180.	1.1	23
34	Avelumab for the treatment of urothelial cancer. Expert Review of Anticancer Therapy, 2018, 18, 421-429.	1.1	9
35	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Annals of Oncology, 2018, 29, 71-83.	0.6	253
36	Immunotherapy for metastatic urothelial carcinoma. Current Opinion in Urology, 2018, 28, 1-7.	0.9	6
37	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. Clinical Genitourinary Cancer, 2018, 16, 117-129.	0.9	28
38	Biomarkers for immunotherapy in urological cancers. Current Opinion in Urology, 2018, 28, 25-28.	0.9	1
39	Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 342-353.	1.8	20

#	ARTICLE	IF	CITATIONS
41	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. <i>Current Urology Reports</i> , 2018, 19, 109.	1.0	47
42	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. <i>BMC Cancer</i> , 2018, 18, 1082.	1.1	42
43	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1303-1313.	1.0	3
44	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1197-1209.	1.0	11
45	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. <i>Future Science OA</i> , 2018, 4, FSO341.	0.9	8
46	The promise of immunotherapy in genitourinary malignancies. <i>Precision Clinical Medicine</i> , 2018, 1, 97-101.	1.3	4
47	HDAC is indispensable for IFN- β -induced B7-H1 expression in gastric cancer. <i>Clinical Epigenetics</i> , 2018, 10, 153.	1.8	38
48	Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation. <i>Frontiers in Oncology</i> , 2018, 8, 612.	1.3	138
49	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1430.	1.6	88
50	Immunotherapy Advances in Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 79.	1.3	5
51	The continuing role of chemotherapy in the management of advanced urothelial cancer. <i>Therapeutic Advances in Urology</i> , 2018, 10, 455-480.	0.9	16
52	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 563.	1.3	35
53	Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies. <i>Scientific Reports</i> , 2018, 8, 17343.	1.6	75
54	Prime time for immunotherapy in advanced urothelial cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 24-32.	0.7	2
55	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. <i>Journal of Experimental Medicine</i> , 2018, 215, 2748-2759.	4.2	34
56	From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. <i>European Urology Oncology</i> , 2018, 1, 486-500.	2.6	35
57	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	1.7	22
58	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5973-5989.	1.0	94

#	ARTICLE	IF	CITATIONS
59	Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 3669-3677.	0.9	2
60	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2018, 15, 116.	1.4	52
62	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.2	0
63	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 125-129.	2.0	19
64	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. <i>Surgical Pathology Clinics</i> , 2018, 11, 877-891.	0.7	0
65	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 707-712.	2.9	28
66	â€DURVITâ€™: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment. <i>BMC Cancer</i> , 2018, 18, 888.	1.1	23
67	Immune checkpoint inhibitors for urothelial carcinoma. <i>Investigative and Clinical Urology</i> , 2018, 59, 285.	1.0	94
68	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 7-16.	1.3	63
69	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.2	26
70	RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 719-724.	1.4	27
71	Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 421-428.e1.	0.9	12
72	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
73	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 209-215.	2.0	29
74	Current Role of Checkpoint Inhibitors in Urologic Cancers. <i>Cancer Treatment and Research</i> , 2018, 175, 241-258.	0.2	5
75	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018, 118, 1434-1441.	2.9	34
76	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	2.9	153
77	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. <i>Oncologist</i> , 2018, 23, 1171-1177.	1.9	29

#	ARTICLE	IF	CITATIONS
78	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
79	Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 771-776.	0.6	16
80	Role of Checkpoint Inhibition in Localized Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 190-198.	2.6	26
81	Basal subtype bladder tumours show a "hot" immunophenotype. <i>Histopathology</i> , 2018, 73, 748-757.	1.6	43
82	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. <i>Future Oncology</i> , 2018, 14, 2683-2690.	1.1	1
83	Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. <i>Human Pathology</i> , 2018, 82, 131-139.	1.1	43
84	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. <i>Diagnostic Pathology</i> , 2018, 13, 47.	0.9	29
85	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 931-940.	0.9	10
86	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1019-1040.	0.9	55
87	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878622.	1.4	5
88	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
89	Novel therapies in urothelial carcinoma: a biomarker-driven approach. <i>Annals of Oncology</i> , 2018, 29, 2302-2312.	0.6	9
90	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
91	Mechanisms of BCG immunotherapy and its outlook for bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 615-625.	1.9	284
92	Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2085-2096.	2.0	38
93	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. , 2018, 6, 4.		118
94	Safety and efficacy of tamsirolimus as second line treatment for patients with recurrent bladder cancer. <i>BMC Cancer</i> , 2018, 18, 194.	1.1	18
96	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. <i>Endocrine Connections</i> , 2018, 7, R196-R211.	0.8	10

#	ARTICLE	IF	CITATIONS
97	Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors. <i>Drugs and Aging</i> , 2018, 35, 409-421.	1.3	6
98	Therapeutic Vaccines for Genitourinary Malignancies. <i>Vaccines</i> , 2018, 6, 55.	2.1	9
99	Antibody-Drug Conjugates in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 247-259.	0.2	29
100	Management of Brain Metastases in the New Era of Checkpoint Inhibition. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 70.	2.0	25
101	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. <i>Clinical Cancer Research</i> , 2018, 24, 6212-6222.	3.2	168
102	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 124-132.	2.0	18
103	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. <i>Molecular Cancer</i> , 2018, 17, 129.	7.9	536
104	Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease. <i>Research and Reports in Urology</i> , 2018, Volume 10, 7-16.	0.6	22
105	Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878831.	1.4	49
106	Drug response to PD-1/PD-L1 blockade: based on biomarkers. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4673-4683.	1.0	55
107	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. <i>Oncolimmunology</i> , 2018, 7, e1460298.	2.1	14
108	Biological effects of radiation on cancer cells. <i>Military Medical Research</i> , 2018, 5, 20.	1.9	110
109	Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1015-e1024.	0.9	12
110	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. <i>Mayo Clinic Proceedings</i> , 2018, 93, 917-936.	1.4	4
111	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 582-597.	2.3	8
112	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	2.3	43
113	Acquired resistance to cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2019, 41, 31-40.	2.8	34
114	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. <i>Cancer Treatment Reviews</i> , 2019, 74, 49-60.	3.4	38

#	ARTICLE	IF	CITATIONS
115	#Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?. BJU International, 2019, 123, 203-207.	1.3	3
116	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. Frontiers in Genetics, 2019, 10, 724.	1.1	12
117	Current advances in BCG-unresponsive non-muscle invasive bladder cancer. Expert Opinion on Investigational Drugs, 2019, 28, 757-770.	1.9	21
118	Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions. Journal of Oncology Practice, 2019, 15, 421-428.	2.5	21
119	Which place for avelumab in the management of urothelial carcinoma?. Expert Opinion on Biological Therapy, 2019, 19, 863-870.	1.4	4
120	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. Future Oncology, 2019, 15, 1505-1524.	1.1	12
121	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	3.4	431
122	Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology, 2019, 16, 465-483.	1.9	119
123	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2019, 381, 338-348.	13.9	885
124	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1. Bladder Cancer, 2019, 5, 131-145.	0.2	11
125	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology, 2019, 10, 1337.	2.2	85
126	Durvalumab in cancer medicine: a comprehensive review. Expert Opinion on Biological Therapy, 2019, 19, 927-935.	1.4	36
127	Programmed death ligand1/programmed death1 inhibition therapy and programmed death ligand1 expression in urothelial bladder carcinoma. Chronic Diseases and Translational Medicine, 2019, 5, 170-177.	0.9	3
128	Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Diagnostic Pathology, 2019, 14, 99.	0.9	41
129	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1692-1700.	2.2	193
130	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 2019, 144, 102812.	2.0	7
131	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	1.8	53
132	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2020, 26, 846-854.	3.2	90

#	ARTICLE	IF	CITATIONS
133	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
134	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. <i>Human Pathology</i> , 2019, 94, 58-63.	1.1	6
135	Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12818.	1.3	46
136	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2019, 12, 92.	6.9	485
137	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 46-55.	2.0	20
138	Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 821-826.	1.9	24
139	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	0.5	69
140	An update on immunotherapy options for urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1265-1274.	1.4	14
141	Current Perspectives in Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1472.	1.7	149
142	Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. <i>Pharmacoeconomics</i> , 2019, 37, 1537-1551.	1.7	12
143	Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. <i>Cell Death and Differentiation</i> , 2019, 26, 2100-2114.	5.0	63
144	Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 291-300.	2.0	14
145	Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial. <i>Oncologist</i> , 2019, 24, 745-e213.	1.9	7
146	Immunotherapy for genitourinary tumors. <i>International Journal of Urology</i> , 2019, 26, 326-333.	0.5	8
147	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	1.8	51
148	Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 4519-4528.	0.9	11
149	Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 4171-4184.	0.9	31
150	Recent advances in the clinical development of immune checkpoint blockade therapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 609-626.	2.1	76

#	ARTICLE	IF	CITATIONS
151	Immunohistochemistry-Enabled Precision Medicine. <i>Cancer Treatment and Research</i> , 2019, 178, 111-135.	0.2	5
152	Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 965-971.	0.6	5
153	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
154	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
155	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 23-35.	2.0	52
156	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 782-789.	0.9	38
157	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
158	Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. <i>Journal of Clinical Oncology</i> , 2019, 37, 2730-2737.	0.8	213
159	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327.	0.3	8
160	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 284-300.	1.8	14
161	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 517-529.	1.5	15
162	Immunohistochemistry. , 2019, , 53-91.		1
163	A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. <i>Annals of Oncology</i> , 2019, 30, 1279-1288.	0.6	438
164	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
165	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	0.8	185
166	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. <i>Journal of Pathology</i> , 2019, 249, 151-165.	2.1	80
167	Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 810.e7-810.e15.	0.8	22
168	Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. <i>Annals of Oncology</i> , 2019, 30, 970-976.	0.6	329

#	ARTICLE	IF	CITATIONS
169	<p></p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>. OncoTargets and Therapy, 2019, Volume 12, 2505-2512.	1.0	17
170	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
171	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. Journal of Immunology, 2019, 202, 3458-3467.	0.4	36
172	Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. , 2019, 7, 105.		103
173	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	1.3	28
174	<p></p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 1791-1801.	1.0	20
175	RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy. Scientific Reports, 2019, 9, 4712.	1.6	40
176	Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-BI) among advanced urothelial cancer patients. Supportive Care in Cancer, 2019, 27, 4189-4198.	1.0	26
177	Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.. Cancer Treatment and Research Communications, 2019, 19, 100124.	0.7	10
178	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research, 2019, 51, 145-156.	0.7	234
179	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunology, Immunotherapy, 2019, 68, 917-926.	2.0	59
180	Combined Inhibition of TGF-Î² Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. Cells, 2019, 8, 320.	1.8	82
181	The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. IScience, 2019, 14, 113-124.	1.9	34
182	Management of metastatic bladder cancer. Cancer Treatment Reviews, 2019, 76, 10-21.	3.4	190
183	Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. Cancer Science, 2019, 110, 1715-1723.	1.7	19
184	Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncology, 2019, 5, 904.	3.4	2
185	From waterfall plots to spaghetti plots in early oncology clinical development. Pharmaceutical Statistics, 2019, 18, 526-532.	0.7	8
186	Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting. Cancer Epidemiology, 2019, 60, 121-127.	0.8	26

#	ARTICLE	IF	CITATIONS
187	New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 91.	3.5	45
189	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 76-84.	2.0	9
190	Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 12.	1.3	20
191	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 177-182.	0.9	11
192	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
193	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019, 21, 24.	1.8	16
194	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. <i>Clinical Pharmacokinetics</i> , 2019, 58, 835-857.	1.6	222
195	PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma. <i>American Journal of Clinical Pathology</i> , 2019, 151, 561-573.	0.4	13
196	PD-L1 testing in urothelial carcinoma: are we there yet?. <i>Translational Andrology and Urology</i> , 2019, 8, S466-S468.	0.6	0
197	Second line immune checkpoint inhibition in urothelial cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 414-420.	0.6	3
198	Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway. <i>Translational Andrology and Urology</i> , 2019, 8, S469-S471.	0.6	3
199	Immune checkpoint inhibitors win the 2018 Nobel Prize. <i>Biomedical Journal</i> , 2019, 42, 299-306.	1.4	62
200	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
202	Immunotherapy in Bladder Cancer. <i>American Journal of Therapeutics</i> , 2022, 29, e334-e337.	0.5	22
203	Advancements in the clinical management of upper tract urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1051-1060.	1.1	6
204	PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis. <i>Bladder Cancer</i> , 2019, 5, 211-223.	0.2	12
205	Evolving Concepts in the Evaluation and Management of Bladder Cancer in Elderly Men. <i>Current Geriatrics Reports</i> , 2019, 8, 331-337.	1.1	0
206	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	2.1	59

#	ARTICLE	IF	CITATIONS
207	Targeting advanced urothelial carcinoma-developing strategies. <i>Current Opinion in Oncology</i> , 2019, 31, 207-215.	1.1	14
208	Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer. <i>Medicine (United States)</i> , 2019, 98, e16324.	0.4	2
209	<p>Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 659-672.	0.7	2
210	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 699-714.	0.6	36
211	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019, 24, 1013-1021.	1.9	15
212	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. <i>Oncologist</i> , 2019, 24, 735-742.	1.9	43
213	The molecular limitations of biomarker research in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 837-848.	1.2	31
214	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
215	Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis. <i>International Immunopharmacology</i> , 2019, 67, 378-385.	1.7	30
216	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
217	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019, 120, 45-53.	2.9	380
218	Systemic treatments for metastatic urothelial carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 201-208.	0.9	12
219	Recent Advances in Anti-cancer Protein/Peptide Delivery. <i>Bioconjugate Chemistry</i> , 2019, 30, 305-324.	1.8	113
220	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 722-731.	1.2	22
221	Treatment of Metastatic Bladder Cancer. , 2019, , 123-137.		0
222	New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 289-301.	1.3	15
223	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16
224	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4

#	ARTICLE	IF	CITATIONS
225	Updates and novel treatments in urothelial carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 648-656.	0.5	27
226	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <i>European Journal of Cancer</i> , 2019, 106, 234-243.	1.3	75
227	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	1.3	9
228	PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 538-540.	0.9	40
229	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 95-105.	1.2	19
230	FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model. <i>International Journal of Cancer</i> , 2019, 144, 345-354.	2.3	12
231	Molecular markers in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 31-40.	1.2	86
232	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
233	Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma. <i>Current Problems in Cancer</i> , 2019, 43, 181-194.	1.0	10
234	The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. <i>European Urology Focus</i> , 2020, 6, 11-13.	1.6	6
235	Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. <i>Cancer</i> , 2020, 126, 432-443.	2.0	13
236	Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 588-596.	2.3	33
237	Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. <i>Histopathology</i> , 2020, 76, 191-200.	1.6	35
238	Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 535-542.	1.4	8
239	Diagnosis and Management of Rare Immune-Related Adverse Events. <i>Oncologist</i> , 2020, 25, 6-14.	1.9	31
240	Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2020, 146, 1851-1861.	2.3	19
241	Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 79.	1.7	29
242	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63

#	ARTICLE	IF	CITATIONS
243	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 165-174.	1.0	27
244	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101925.	3.4	73
245	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
246	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 125-136.	1.0	51
247	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
248	Erdafitinib for the treatment of metastatic bladder cancer. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1-6.	1.3	63
249	Bacillus Calmette-Guérin in unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies. <i>International Journal of Urology</i> , 2020, 27, 108-116.	0.5	22
250	Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. <i>Clinical Cancer Research</i> , 2020, 26, 787-792.	3.2	44
251	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
252	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	0.8	450
253	Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma. <i>Histopathology</i> , 2020, 77, 67-78.	1.6	4
254	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. , 2020, 8, e001246.		49
255	Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis. <i>Oncology</i> , 2020, 98, 876-883.	0.9	18
256	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
257	Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7268.	1.8	33
258	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	15.2	193
259	Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. <i>European Urology Focus</i> , 2021, 7, 1061-1066.	1.6	8
260	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. <i>Urologic Clinics of North America</i> , 2020, 47, 487-510.	0.8	10

#	ARTICLE	IF	CITATIONS
261	Optimizing frontline therapy in advanced urothelial cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 983-985.	0.6	3
262	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. <i>World Journal of Urology</i> , 2020, 39, 4055-4065.	1.2	11
263	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. <i>Medicine (United States)</i> , 2020, 99, e21273.	0.4	9
264	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568279.	1.3	11
265	Optimizing Sequence of PD-L1 Immune-Checkpoint Inhibitors and Radiation Therapy in Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 295-302.	0.2	4
266	The human microbiome and genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2020, 8, 1245-1245.	0.7	17
267	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. <i>Seminars in Oncology</i> , 2020, 47, 367-379.	0.8	6
268	Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. <i>Seminars in Cancer Biology</i> , 2022, 86, 1033-1057.	4.3	14
269	Optimal Systemic Treatment of Advanced Bladder Cancer—A Moving Target. <i>Cancers</i> , 2020, 12, 3607.	1.7	1
270	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091.	1.6	4
271	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
272	Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1980.	3.8	817
273	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 404-423.	157.7	507
274	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205
275	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective. <i>Frontiers in Immunology</i> , 2020, 11, 1508.	2.2	60
276	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	1.4	78
277	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5390.	1.8	48
278	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1155-1164.	5.1	274

#	ARTICLE	IF	CITATIONS
279	Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options. <i>Cancer Treatment Reviews</i> , 2020, 89, 102072.	3.4	14
280	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
281	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	7.7	179
282	Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 568809.	1.3	3
283	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	1.7	15
284	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7935.	1.8	17
285	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
286	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	5.1	324
287	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.	13.9	802
288	Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1139-1146.	1.3	11
289	Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. , 2020, 8, e000650.		23
290	Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1097-1107.	0.6	19
291	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
292	Enfortumab vedotin â€œ next game-changer in urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 801-809.	1.4	17
293	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. <i>Cancers</i> , 2020, 12, 3173.	1.7	36
294	Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. <i>Radiation Oncology</i> , 2020, 15, 254.	1.2	62
295	Nuevas inmunoterapias en el cÃ¡ncer de vejiga no mÃºsculo-invasivo de alto riesgo: estado actual y perspectivas de futuro. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2020, 44, 574-585.	0.3	3
296	Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 27-34.	0.8	4

#	ARTICLE	IF	CITATIONS
297	New immunotherapies for high-risk non-muscle invasive bladder cancer: Current state and future perspectives. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 574-585.	0.2	1
298	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	2.2	100
299	Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 428-440.	0.9	8
300	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
301	Scientifically based combination therapies with immunooncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
302	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
303	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1736-1752.	1.1	10
304	Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. <i>Cancers</i> , 2020, 12, 1181.	1.7	69
305	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 547-556.	0.9	12
306	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. <i>Bladder Cancer</i> , 2020, 6, 43-52.	0.2	2
307	An evaluation of avelumab for the treatment of genitourinary tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 971-979.	1.4	4
308	PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1385-1392.	0.6	12
310	Immune Checkpoint Inhibitors in Genitourinary Malignancies. <i>Current Oncology</i> , 2020, 27, 69-77.	0.9	13
311	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. <i>American Journal of Surgical Pathology</i> , 2020, 44, e30-e46.	2.1	38
312	Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1274-1288.	2.3	27
313	Breakthrough therapy-designated oncology drugs: are they rightfully criticized?. <i>Drug Discovery Today</i> , 2020, 25, 1580-1584.	3.2	3
314	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
315	PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs. <i>Life Sciences</i> , 2020, 256, 117899.	2.0	45

#	ARTICLE	IF	CITATIONS
316	Androgen receptor in bladder cancer: A promising therapeutic target. <i>Asian Journal of Urology</i> , 2020, 7, 284-290.	0.5	25
317	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
318	From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses. <i>Cell Death Discovery</i> , 2020, 6, 48.	2.0	18
319	The emerging role of antibody-drug conjugates in urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 551-561.	1.1	23
320	Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 1088.	2.2	61
321	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
322	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
323	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
324	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
325	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020, 14, E373-E382.	0.3	8
326	Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. <i>Journal of Pancreatic Cancer</i> , 2020, 6, 21-31.	1.6	31
327	Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis. <i>Cancer Medicine</i> , 2020, 9, 4014-4025.	1.3	25
328	Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8+ T Cells and Elevated β -Catenin Activation Compared with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3791-3802.	3.2	13
329	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , 2020, 12, 819-831.	1.0	10
330	Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100179.	0.7	4
331	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. <i>Seminars in Cancer Biology</i> , 2022, 79, 18-43.	4.3	35
332	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 4531-4541.	3.2	46
333	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40

#	ARTICLE	IF	CITATIONS
334	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>Oncolmmunology</i> , 2020, 9, 1708065.	2.1	41
335	Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 5.	1.6	12
336	The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials. <i>Clinical and Translational Oncology</i> , 2020, 22, 1750-1761.	1.2	2
337	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.3	13
338	Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 191-199.	0.6	2
339	Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder. <i>Journal of Clinical Pathology</i> , 2020, 73, 519-522.	1.0	6
340	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
341	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. <i>Cancers</i> , 2020, 12, 192.	1.7	30
342	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. <i>Nature Reviews Urology</i> , 2020, 17, 77-106.	1.9	91
343	<p>Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1-15.	1.0	44
344	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 351-360.e3.	0.9	14
345	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
346	Optimal PD-L1â€“high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. <i>PLoS ONE</i> , 2020, 15, e0231936.	1.1	16
348	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	3.2	27
349	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	0.9	1
350	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
351	Emerging treatments in advanced urothelial cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 232-239.	1.1	2
352	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. <i>Current Opinion in Urology</i> , 2020, 30, 457-466.	0.9	2

#	ARTICLE	IF	CITATIONS
353	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1797-1806.	0.8	102
354	Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2286.	1.8	61
355	Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1-9.	2.8	203
356	VEGF inhibition in urothelial cancer: the past, present and future. <i>World Journal of Urology</i> , 2021, 39, 741-749.	1.2	13
357	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , 2021, 79, 62-79.	0.9	532
358	PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. <i>World Journal of Urology</i> , 2021, 39, 1345-1355.	1.2	13
359	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
360	Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 75.e1-75.e8.	0.8	9
361	From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. <i>Immunotherapy</i> , 2021, 13, 67-77.	1.0	2
362	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 7.	1.3	6
363	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 223-249.	9.6	956
364	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	2.0	26
365	The impact of pre-analytical parameters on class II biomarkers by immunohistochemistry: concordance across four tissue processing protocols. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 985-993.	1.4	2
366	Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 299-313.	1.1	6
367	Immune checkpoint inhibition in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1357-1367.	1.2	27
368	Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. <i>Annals of Pharmacotherapy</i> , 2021, 55, 772-782.	0.9	10
369	Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. <i>World Journal of Urology</i> , 2021, 39, 1331-1343.	1.2	34
370	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 867-887.	2.4	9

#	ARTICLE	IF	CITATIONS
371	Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	7
372	Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions. <i>Oncology & Hematology Review</i> , 2021, 16, 82.	0.2	1
373	Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma. <i>Oncolimmunology</i> , 2021, 10, 1887551.	2.1	3
374	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110216.	0.6	12
375	Review of immune checkpoint inhibitors in immuno-oncology. <i>Advances in Pharmacology</i> , 2021, 91, 111-139.	1.2	43
377	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	10
378	Clinical Trials in Localized Muscle-Invasive Bladder Cancer. , 2021, , 355-363.		0
379	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	1.7	153
380	Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors. , 2021, , 31-47.		0
381	Immunotherapy for Metastatic Urothelial Carcinoma. , 2021, , 305-313.		0
382	Bladder Cancer Tissue-Based Biomarkers. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, 53-71.	0.2	0
383	Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. <i>Oncogenesis</i> , 2021, 10, 3.	2.1	25
384	Medical Treatment with Targeted Therapy for Metastatic Urothelial Bladder Carcinoma. , 2021, , 199-209.		1
386	Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. <i>Current Oncology Reports</i> , 2021, 23, 24.	1.8	5
387	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 30-39.	0.1	0
388	Monoclonal Antibodies: A Prospective and Retrospective View. <i>Current Medicinal Chemistry</i> , 2021, 28, 435-471.	1.2	8
389	Bladder cancer cell�intrinsic PD�L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. <i>Cancer Medicine</i> , 2021, 10, 2137-2152.	1.3	26
390	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 414-419.	0.2	3

#	ARTICLE	IF	CITATIONS
391	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	1.7	41
392	Status of Metastatic Bladder Cancer Treatment Illustrated by a Case. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151113.	0.7	2
393	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. <i>Current Drug Targets</i> , 2021, 22, 162-170.	1.0	16
394	The evolving landscape of immunotherapy in solid tumors. <i>Journal of Surgical Oncology</i> , 2021, 123, 798-806.	0.8	17
395	Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 627706.	1.8	26
396	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
397	A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation. <i>Statistics in Biopharmaceutical Research</i> , 0, , 1-12.	0.6	1
398	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. <i>JCSM Rapid Communications</i> , 2021, 4, 232-244.	0.6	6
399	Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. <i>Cancer Treatment Reviews</i> , 2021, 93, 102142.	3.4	27
400	PD-L1 as a Potential Target in Cancer Therapy (Review). <i>Drug Development and Registration</i> , 2021, 10, 31-36.	0.2	3
401	SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study. <i>Thoracic Cancer</i> , 2021, 12, 1373-1381.	0.8	15
402	Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma. <i>Pathology Research and Practice</i> , 2021, 219, 153364.	1.0	11
403	Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 410-421.	2.0	38
404	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <i>Annals of Translational Medicine</i> , 2021, 9, 423-423.	0.7	6
405	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 343-350.	1.9	75
406	Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. <i>European Urology Focus</i> , 2022, 8, 483-490.	1.6	1
407	The evolving treatment landscape of advanced urothelial carcinoma. <i>Current Opinion in Oncology</i> , 2021, 33, 221-230.	1.1	6
408	Predictive biomarkers in bladder cancer. <i>Biomarkers in Medicine</i> , 2021, 15, 241-246.	0.6	2

#	ARTICLE	IF	CITATIONS
409	Coming of Age of Immunotherapy of Urothelial Cancer. <i>Targeted Oncology</i> , 2021, 16, 283-294.	1.7	2
410	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	1.9	23
411	Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions. <i>Kidney Cancer</i> , 2021, 5, 9-20.	0.2	1
412	Unraveling the Role of Immune Checkpoints in Leishmaniasis. <i>Frontiers in Immunology</i> , 2021, 12, 620144.	2.2	18
413	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. <i>AAPS Journal</i> , 2021, 23, 39.	2.2	356
414	Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, whatâ€™s new?. <i>Immunotherapy</i> , 2021, 13, 459-463.	1.0	2
415	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
416	Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma. <i>Clinical Journal of Oncology Nursing</i> , 2021, 25, E1-E9.	0.3	10
417	Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study. <i>Cancers</i> , 2021, 13, 1623.	1.7	4
418	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 540-546.	0.9	10
419	Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. <i>International Immunopharmacology</i> , 2021, 93, 107403.	1.7	30
420	The Current Landscape of Immune Checkpoint Blockade in Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 235-248.	0.8	8
421	Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 629646.	1.3	2
422	Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. <i>Molecular Cancer Research</i> , 2021, 19, 1422-1436.	1.5	3
423	Myeloid Cellâ€™associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , 2021, 27, 4287-4300.	3.2	42
424	Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. <i>Advances in Therapy</i> , 2021, 38, 2759-2778.	1.3	11
425	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	15.2	56
426	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12

#	ARTICLE	IF	CITATIONS
427	<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. , 2021, 9, e002127.		24
428	Effectiveness and safety of combined therapy versus monotherapy based on immune checkpoint inhibitors and/or targeted drugs as salvage treatment for advanced urothelial carcinoma: a systematic review and meta-analysis. Translational Cancer Research, 2021, 10, 2091-2107.	0.4	0
429	The Landscape of Antibody-drug Conjugates in Urothelial Cancer. Advances in Oncology, 2021, 1, 273-282.	0.1	0
430	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2111113.	2.8	17
431	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. Cancers, 2021, 13, 2452.	1.7	11
432	Atlantis exploration: predictive biomarkers to immunotherapy response. Onkourologiya, 2021, 17, 167-177.	0.1	1
433	Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model. Journal of Urology, 2021, 205, 1336-1343.	0.2	12
434	Biomarker approach harnessed in trials of personalized medicine for bladder cancer. Nature Medicine, 2021, 27, 761-763.	15.2	5
435	Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 863-873.	1.4	13
436	Advances in the management of urothelial carcinoma: is immunotherapy the answer?. Expert Opinion on Pharmacotherapy, 2021, 22, 1743-1759.	0.9	3
437	Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation. Journal of Pathology and Translational Medicine, 2021, 55, 163-170.	0.4	5
438	Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report. Frontiers in Oncology, 2021, 11, 646322.	1.3	2
439	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treatment Reviews, 2021, 97, 102187.	3.4	31
440	Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Frontiers in Immunology, 2021, 12, 694763.	2.2	16
441	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Frontiers in Oncology, 2021, 11, 641428.	1.3	32
442	Current Therapy for Metastatic Urothelial Carcinoma. Hematology/Oncology Clinics of North America, 2021, 35, 469-493.	0.9	4
443	Drugâ€“induced immuneâ€“mediated thrombocytopenia secondary to durvalumab use. Clinical Case Reports (discontinued), 2021, 9, e04227.	0.2	5
444	The Evolving Landscape of Antibodyâ€“Drug Conjugates for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 183-193.	0.9	6

#	ARTICLE	IF	CITATIONS
445	Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma. , 2021, 3, 115-136.		2
446	Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e182-e189.	1.8	7
447	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Annals of Allergy, Asthma and Immunology, 2021, 126, 630-638.	0.5	23
448	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 248-253.	1.2	10
449	Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models. Frontiers in Bioengineering and Biotechnology, 2021, 9, 690358.	2.0	6
450	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochimica Et Biophysica Sinica, 2021, 53, 961-978.	0.9	4
451	Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. International Immunopharmacology, 2021, 95, 107498.	1.7	45
452	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
453	Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single Center Experience Over 25 Years and Evaluation of PD-L1 Expression. Cancer Research and Treatment, 2021, , .	1.3	1
454	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 7201.	1.8	8
455	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. Journal of Inflammation Research, 2021, Volume 14, 3077-3088.	1.6	5
456	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. European Journal of Cancer, 2021, 151, 35-48.	1.3	24
457	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9
458	Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma. Urology, 2021, 153, 244-249.	0.5	2
459	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1244-1256.	0.9	4
460	Inhibitors of immune checkpointsâ€”PD-1, PD-L1, CTLA-4â€”new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer and Metastasis Reviews, 2021, 40, 949-982.	2.7	72
461	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799.	1.9	52
462	High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. Future Oncology, 2021, 17, 2893-2905.	1.1	6

#	ARTICLE	IF	CITATIONS
463	Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 723066.	1.6	1
464	Urothelial carcinoma in the era of immune checkpoint inhibitors. <i>Immunotherapy</i> , 2021, 13, 953-964.	1.0	5
465	Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation. <i>Cancer Letters</i> , 2021, 513, 14-25.	3.2	22
466	Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 16460.	1.6	3
467	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2474-2485.	0.8	250
468	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4411.	1.7	31
469	The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. <i>Aging</i> , 2021, 13, 20468-20480.	1.4	3
470	Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4343.	1.7	8
471	Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 705294.	1.3	5
472	Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group. <i>Cancers</i> , 2021, 13, 4762.	1.7	7
473	Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. <i>Cancers</i> , 2021, 13, 4548.	1.7	16
474	<sc>First-Line</sc> Durvalumab in Addition to Etoposide and Platinum for <sc>Extensive-Stage</sc> Small Cell Lung Cancer: A U.S.-Based <sc>Cost-Effectiveness</sc> Analysis. <i>Oncologist</i> , 2021, 26, e2013-e2020.	1.9	10
475	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 528-547.	0.8	0
476	Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10612.	1.8	7
477	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 425-433.	0.9	15
479	Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway. <i>Life Sciences</i> , 2021, 282, 119813.	2.0	21
480	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 631-641.	0.8	7
481	Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 457-465.	0.9	8

#	ARTICLE	IF	CITATIONS
482	Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 542140.	1.3	21
483	Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110297.	0.9	9
484	Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. <i>Translational Andrology and Urology</i> , 2021, 10, 4051-4061.	0.6	6
485	The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. <i>Cancers</i> , 2021, 13, 494.	1.7	10
486	Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110449.	0.6	18
487	Metastatic Urothelial Cancer: a rapidly changing treatment landscape. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110473.	1.4	19
488	Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 4014-4021.	0.6	7
489	Role of immunotherapy in bladder cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100296.	0.7	41
490	Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review. <i>Translational Andrology and Urology</i> , 2021, 10, 4022-4035.	0.6	3
491	First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma. <i>Oncology</i> , 2021, 99, 622-631.	0.9	4
492	A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	1.3	10
493	Current Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 107-147.	0.8	3
494	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
495	JAVELIN: avelumab another spear to fight urothelial carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 5-7.	5.1	2
496	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020, 204, 1173-1179.	0.2	47
499	CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. <i>JCI Insight</i> , 2018, 3, .	2.3	40
500	New and Emerging Therapies in the Management of Bladder Cancer. <i>F1000Research</i> , 2020, 9, 1146.	0.8	4
501	An Update on Immune Checkpoint Inhibitor-related Hypophysitis. <i>US Endocrinology</i> , 2020, 16, 117.	0.3	3

#	ARTICLE	IF	CITATIONS
502	The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. <i>Aging</i> , 2021, 13, 2279-2293.	1.4	4
503	Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. <i>Oncotarget</i> , 2018, 9, 34066-34078.	0.8	45
504	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
505	Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
506	Emerging biomarkers and targeted therapies in urothelial carcinoma. <i>Annals of Translational Medicine</i> , 2018, 6, 250-250.	0.7	33
507	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	0.7	77
508	Perioperative immunotherapy for muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2976-2985.	0.6	5
509	<p>Current Molecular Targeted Agents for Advanced Gastric Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4075-4088.	1.0	17
510	Targeting PD-L1 Protein: Translation, Modification and Transport. <i>Current Protein and Peptide Science</i> , 2018, 20, 82-91.	0.7	20
511	PD1/PD-L1 Axis in Uro-oncology. <i>Current Drug Targets</i> , 2020, 21, 1293-1300.	1.0	6
512	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 242-257.	0.8	5
513	Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 205-216.	3.9	1
514	Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 663-672.	3.9	13
515	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <i>Acta Haematologica Polonica</i> , 2018, 49, 207-227.	0.1	5
516	Expression of PD-L1 for Predicting Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2020, 27, 656-663.	0.9	8
517	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immune evaluation (Review). <i>Oncology Reports</i> , 2020, 44, 424-437.	1.2	18
518	Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 834-853.	0.7	10
519	Low doses in immunotherapy: Are they effective?. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 54.	0.1	12

#	ARTICLE	IF	CITATIONS
520	Adverse effects of immuno-oncology drugs—Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. <i>Indian Journal of Cancer</i> , 2019, 56, 10.	0.2	3
521	Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 355-361.	2.3	8
522	Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ- and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy. <i>PeerJ</i> , 2017, 5, e3921.	0.9	11
524	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. <i>Cancers</i> , 2021, 13, 5065.	1.7	13
525	Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer. <i>Molecular Pharmaceutics</i> , 2021, 18, 4015-4028.	2.3	24
526	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
527	The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11061.	1.8	49
528	Novel Options in Metastatic and Non-surgically Curable Bladder Cancer. <i>European Oncology and Haematology</i> , 2018, 14, 87.	0.0	0
529	Programmed Death-1 and Programmed Death Ligand-1 Blockade for Advanced Urothelial Carcinoma. <i>Urological Science</i> , 2019, 30, 2-7.	0.2	2
531	Clinicopathological correlation of immune response in human cancers. <i>Oncotarget</i> , 2019, 10, 5859-5870.	0.8	0
532	Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1269-1274.	1.3	4
533	Improving Outcomes for Patients With Advanced Urothelial Carcinoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 285-289.	0.2	0
534	Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies. <i>The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products</i> , 2020, 10, 96-110.	0.1	3
536	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
537	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. <i>Cancers</i> , 2021, 13, 5415.	1.7	13
538	The Tumor Microenvironment of Bladder Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 275-290.	0.8	18
539	Therapy Response Imaging in Genitourinary Malignancies. <i>Medical Radiology</i> , 2020, , 139-157.	0.0	0
540	Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist's Perspective. <i>Bladder Cancer</i> , 2020, 6, 425-433.	0.2	0

#	ARTICLE	IF	CITATIONS
541	Immunotherapy in urothelial cancer. <i>Onkologie (Czech Republic)</i> , 2019, 13, 209-213.	0.0	0
542	Metastasiertes Urothelkarzinom. <i>Springer Reference Medizin</i> , 2020, , 1-11.	0.0	0
543	Targeting the Immune System in Pancreatic Cancer. <i>Molecular and Translational Medicine</i> , 2020, , 203-218.	0.4	0
544	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
545	Immunotherapy in Bladder and Renal Cancers. , 2020, , 451-474.		0
546	Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. <i>Cancer Cell International</i> , 2021, 21, 589.	1.8	17
547	Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma. <i>Molecular Carcinogenesis</i> , 2021, , .	1.3	0
548	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. <i>Clinical Cancer Research</i> , 2022, 28, 489-497.	3.2	36
549	Immunotherapy for Metastatic Urothelial Cancer. , 2021, , 201-213.		0
550	Immunotherapies For Cancer, a Promising Cure?. , 2020, , .		0
551	Transcriptional changes associated with growth of muscle-invasive bladder cancer cell lines in nude mice. <i>American Journal of Clinical and Experimental Urology</i> , 2018, 6, 138-148.	0.4	5
552	Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, S62-S64.	0.6	0
553	Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis. <i>Indian Journal of Urology</i> , 2019, 35, 101-115.	0.2	1
554	The Role of Immunotherapy in Urologic Cancers. <i>Missouri Medicine</i> , 2020, 117, 127-132.	0.3	1
556	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 485-500.	0.3	5
557	The Hippo pathway: an emerging role in urologic cancers. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 301-317.	0.4	1
558	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 710943.	1.6	6
559	Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103534.	2.0	5

#	ARTICLE	IF	CITATIONS
560	Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 385-395.	1.4	5
561	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients. Cancers, 2021, 13, 5841.	1.7	12
562	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Communication and Signaling, 2021, 19, 117.	2.7	25
563	Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. Cancers, 2021, 13, 6016.	1.7	19
564	Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research. Frontiers in Oncology, 2021, 11, 784947.	1.3	37
565	Upper Tract Urothelial Carcinoma. , 2022, , 155-207.		0
566	Urotheltumoren: Immuntherapien auf dem PrÃ¼fstand. , 0, , .		0
568	Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 143-192.	0.8	2
569	Avelumab in locally advanced or metastatic urothelial carcinoma. Expert Review of Anticancer Therapy, 2022, , .	1.1	1
572	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncology, The, 2022, 23, 248-258.	5.1	73
573	Breast Cancer Immunotherapy: From Biology to Current Clinical Applications. European Medical Journal (Chelmsford, England), 0, , 113-124.	3.0	2
574	Role of immunotherapy in Bacillus Calmette-Gueÿrin unresponsive: non-muscle invasive bladder cancer. Translational Cancer Research, 2020, 9, 6537-6545.	0.4	5
575	PHENOMENON OF DEVELOPMENT OF PROFESSIONAL COMPETENCE OF SOCIAL WORKERS IN RESEARCH OF DOMESTIC SCIENTISTS. Scientific Bulletin of Uzhhorod University Series Â«Pedagogy Social WorkÂ», 2020, .	0.0	0
576	Research progress of tumor targeted drug delivery based on PD-1/PD-L1. International Journal of Pharmaceutics, 2022, 616, 121527.	2.6	16
577	Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1097-1105.	1.2	5
579	Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International, 2022, 22, 2.	1.8	83
580	Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. Cells, 2022, 11, 139.	1.8	6
581	Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. Current Oncology, 2022, 29, 687-697.	0.9	9

#	ARTICLE	IF	CITATIONS
583	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , 2022, 2, 39-48.	0.7	4
584	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. <i>European Journal of Cancer</i> , 2022, 163, 55-65.	1.3	5
585	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. <i>Biomedicines</i> , 2022, 10, 411.	1.4	11
586	Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUC Multidisciplinary Working Group. <i>Cancers</i> , 2022, 14, 1130.	1.7	4
587	MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2602.	1.8	1
588	Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. <i>Pharmaceuticals</i> , 2022, 15, 335.	1.7	35
590	The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Cancers</i> , 2022, 14, 1640.	1.7	3
591	Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. <i>Life</i> , 2022, 12, 360.	1.1	1
592	Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. <i>JCO Precision Oncology</i> , 2022, 6, e2100390.	1.5	2
593	Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2022, 14, 1669.	1.7	6
594	Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 189-194.	0.9	2
595	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	5.8	3
596	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. <i>Nature Communications</i> , 2022, 13, 1797.	5.8	23
597	Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. <i>Translational Oncology</i> , 2022, 19, 101387.	1.7	2
598	The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 410-419.	0.8	3
599	Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 673918.	1.6	2
600	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
601	Case Report: Erdafitinib-induced Central Serous Chorioretinopathy. <i>Optometry and Vision Science</i> , 2022, 99, 88-92.	0.6	4

#	ARTICLE	IF	CITATIONS
602	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	5.8	37
603	Use of Immunotherapy in Clinical Management of Genitourinary Cancers – a Review. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100564.	0.7	3
616	Progress in the development of tissue-based biomarkers for urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 605-619.	1.1	1
619	MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. <i>Future Oncology</i> , 2022, 18, 2465-2473.	1.1	40
620	Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 410.e11-410.e18.	0.8	1
622	Natural killer cells: unlocking new treatments for bladder cancer. <i>Trends in Cancer</i> , 2022, 8, 698-710.	3.8	5
623	Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head&neck cancer. <i>Cancer Medicine</i> , 2022, 11, 2550-2560.	1.3	25
624	A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. <i>Investigative and Clinical Urology</i> , 2022, 63, 373.	1.0	5
625	Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	27
626	Insights on recent innovations in bladder cancer immunotherapy. <i>Cancer Cytopathology</i> , 2022, 130, 667-683.	1.4	8
628	Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
629	Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy. <i>Cancer Management and Research</i> , 0, Volume 14, 1945-1960.	0.9	5
630	Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. <i>Oncologist</i> , 2022, 27, e703-e722.	1.9	2
631	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
632	Lower neutrophil&lymphocyte ratio and positive programmed cell death ligand&1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma. <i>Cancer Medicine</i> , 2022, 11, 4236-4245.	1.3	7
633	Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). <i>Journal of Clinical Oncology</i> , 2023, 41, 43-53.	0.8	24
634	A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.. <i>Pathology Research and Practice</i> , 2022, 236, 153983.	1.0	3
635	CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
636	Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The <sc>FUSION NHL</sc> 001 trial. <i>Cancer Reports</i> , 2023, 6, .	0.6	6
637	Urothelial Carcinoma (Bladder Cancer and Upper Tracts). , 2023, , 309-329.e4.		0
638	Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
639	The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Urinary Tract Tumors. <i>European Urology</i> , 2022, 82, 469-482.	0.9	71
640	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1
641	Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. <i>Annals of Oncology</i> , 2022, 33, 1149-1158.	0.6	73
642	NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 866-878.	2.3	97
643	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
644	Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 4871-4884.	3.2	27
645	The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. <i>Pathology</i> , 2023, 55, 19-30.	0.3	3
646	Cutaneous Reactions to Oncologic Immunotherapy. <i>Updates in Clinical Dermatology</i> , 2022, , 317-330.	0.1	0
647	Predictive Biomarkers in the Management of Bladder Cancer: Perspectives in an Evolving Therapeutic Landscape. <i>Soci�t� Internationale D'urologie Journal</i> , 2022, 3, 245-257.	0.2	1
648	Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
649	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
651	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. <i>Life Sciences</i> , 2022, 310, 121138.	2.0	14
652	The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
653	Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2022, 14, 5431.	1.7	8
654	Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 286-294.	0.9	6

#	ARTICLE	IF	CITATIONS
655	The cancer behavior and current treatment strategy for upper urinary tract cancer. <i>Urological Science</i> , 2022, 33, 161.	0.2	5
656	Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a narrative review. <i>Translational Andrology and Urology</i> , 2022, 11, 1747-1761.	0.6	6
657	Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 177-195.	0.9	1
658	A novel prognostic model based on cellular senescence-related gene signature for bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
659	Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives. <i>Urologia</i> , 2023, 90, 3-10.	0.3	2
660	Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1601-1616.	1.1	4
661	Switch Maintenance Therapy for Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2022, 8, 359-369.	0.2	0
662	Integrated molecular analyses of an interferon- γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. <i>Heliyon</i> , 2022, 8, e12102.	1.4	0
663	Construction and experimental validation of a B cell senescence-related gene signature to evaluate prognosis and immunotherapeutic sensitivity in bladder cancer. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	4
664	A rare case of bladder cancer that metastasized to brain, heart, and lung lymph nodes benefited from immunotherapy. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
665	PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer. <i>BJUI Compass</i> , 2023, 4, 322-330.	0.7	3
666	Optimal Systemic Treatment of Advanced Bladder Cancer Calls for a Multidisciplinary Approach. <i>Cancers</i> , 2023, 15, 559.	1.7	0
667	The role of switch maintenance therapy in urothelial cancers. <i>Therapeutic Advances in Urology</i> , 2023, 15, 175628722211477.	0.9	2
668	Immunotherapy for Urothelial Carcinoma. , 2023, , 1-12.		0
669	The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. <i>Cancers</i> , 2023, 15, 284.	1.7	7
670	Tumor immunology. , 2023, , 245-452.		0
671	A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. <i>European Urology</i> , 2023, 83, 486-494.	0.9	11
672	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. <i>Life Sciences</i> , 2023, 318, 121459.	2.0	6

#	ARTICLE	IF	CITATIONS
673	Liquid biopsy and immunotherapy: is all that glitter gold?. , 2023, , 83-117.		0
674	Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311597.	0.8	0
675	Evolving systemic management of urothelial cancers. <i>Current Opinion in Oncology</i> , 2023, 35, 186-199.	1.1	2
676	Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase 2 study. <i>Cancer Medicine</i> , 2023, 12, 12106-12117.	1.3	2
677	Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. <i>Cancer Letters</i> , 2023, 562, 216167.	3.2	5
678	Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. <i>International Immunopharmacology</i> , 2023, 119, 110158.	1.7	2
679	Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 38, e00794.	2.1	2
680	Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2023, 9, 264-274.	1.6	1
681	Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 3122-3134.	0.8	20
682	First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study. <i>Anticancer Research</i> , 2023, 43, 1331-1339.	0.5	1
683	Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2023, 28, 17-26.	1.0	0
684	Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies. <i>Cells</i> , 2023, 12, 841.	1.8	3
685	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
686	Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 251-265.	0.8	1
687	Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. <i>Journal of Clinical Oncology</i> , 2023, 41, 3225-3235.	0.8	4
688	Single Drug Therapy of PD-1/PD-L1 Checkpoint Inhibitors for Advanced Urothelial Bladder Cancer. , 0, 36, 29-35.		0
689	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. <i>European Urology</i> , 2023, 84, 49-64.	0.9	98
690	Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020. <i>Cancers</i> , 2023, 15, 2069.	1.7	1

#	ARTICLE	IF	CITATIONS
691	The clinical safety and efficacy of targeted PD-L1 therapy with durvalumab in solid tumors. <i>Current Drug Targets</i> , 2023, 24, .	1.0	1
692	Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. <i>Molecular and Cellular Biochemistry</i> , 2024, 479, 127-170.	1.4	1
693	Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer. <i>PeerJ</i> , 0, 11, e15088.	0.9	0
694	Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 407-418.	1.4	2
695	The prognostic value of thyroid hormone levels in immunotherapy-treated patients with metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2023, , .	0.9	0
708	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 13477-13494.	1.2	2
724	Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment. , 2023, 40, .		0
725	Progress in systemic therapy for advanced-stage urothelial carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 8-27.	12.5	1
734	The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2024, 150, .	1.2	0
740	Ureteral Tumors. , 2023, , 369-406.		0